A MAJORITY
of preclinical and clinical non-oncology programs supported by
POPULATION GENETICS
Invested nearly
$19B
in R&D between
2014 and 2018
Since 2014,
R&D productivity
>2.5X
industry
average

Reduced R&D cycle times
~36 months in last 5 years
reflecting commitment to bring medicines to patients as quickly and safely as possible
Filed 10 Investigational New
Drug Applications
and initiatiated 10 First-In-Human
studies
Early-stage
oncology pipeline includes
20
molecules
in development

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible.

Download Pipeline Chart

*   Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

   In addition to the above programs, AMJEVITA™/AMGEVITA™, MVASI™, and KANJINTI™ have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA™ has been approved by the FDA.